Shire Given Buy Rating at Citigroup Inc. (SHP)
Shire (LON:SHP)‘s stock had its “buy” rating reiterated by equities research analysts at Citigroup Inc. in a research note issued to investors on Tuesday, AR Network reports.
SHP has been the subject of a number of other recent research reports. Analysts at JPMorgan Chase & Co. upgraded shares of Shire (LON:SHP) from a “neutral” rating to an “overweight” rating in a research note to investors on Monday. They now have a GBX 3,000 ($48.40) price target on the stock, up previously from GBX 2,270 ($36.62). Separately, analysts at AlphaValue reiterated a “reduce” rating on shares of Shire (LON:SHP) in a research note to investors on Thursday, September 26th. They now have a GBX 2,338 ($37.72) price target on the stock. Finally, analysts at Morgan Stanley reiterated an “overweight” rating on shares of Shire (LON:SHP) in a research note to investors on Wednesday, September 25th. They now have a GBX 2,750 ($44.37) price target on the stock. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating, sixteen have assigned a buy rating and one has issued a strong buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of GBX 2,055.02 ($33.16).
Shares of Shire (LON:SHP) opened at 2468.00 on Tuesday. Shire has a one year low of GBX 1682.00 and a one year high of GBX 2602.00. The stock has a 50-day moving average of GBX 2432.08 and a 200-day moving average of GBX 2167.18. The company’s market cap is £13.564 billion.
Shire plc (LON:SHP) is a specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.